Specialty & Advanced Medicines in India | Kasdap Healthcare

What Are Specialty Medicines?

The term 'specialty medicines' encompasses a broad and growing category of pharmaceutical products that share several common characteristics: they treat chronic, rare, or complex conditions; they require specialised handling, administration, or patient monitoring; they are often high-value; and they are typically manufactured using sophisticated technology platforms that go beyond conventional small-molecule synthesis.

Globally, specialty medicines now account for over 50% of total pharmaceutical expenditure by value, despite representing a smaller proportion of prescription volume. In India, the specialty segment is growing at 15–18% annually — significantly faster than the overall pharma market — driven by improving diagnosis rates, insurance coverage expansion, and the availability of affordable biosimilars.

Oncology Supportive Care: Improving Cancer Treatment Tolerability

Cancer treatment in India has expanded dramatically over the past decade, with oncology centres now present across tier-2 and tier-3 cities. Alongside cytotoxic chemotherapy and targeted agents, supportive care medicines play an essential role in enabling patients to complete their treatment courses and maintain quality of life.

Antiemetics

Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects of cancer treatment. Modern antiemetic regimens combine agents from multiple classes:

• 5-HT3 receptor antagonists: Ondansetron, Granisetron, and Palonosetron for acute CINV management
• NK1 receptor antagonists: Aprepitant and Fosaprepitant for high emetogenic risk chemotherapy regimens
• Dexamethasone: A cornerstone of most antiemetic combinations, with broad efficacy across CINV types
• Olanzapine: Increasingly used for delayed CINV and breakthrough nausea

Haematopoietic Growth Factors

Granulocyte Colony-Stimulating Factors (G-CSFs) — Filgrastim and Pegfilgrastim — reduce the duration and severity of chemotherapy-induced neutropenia, preventing febrile neutropenia and allowing chemotherapy dose maintenance. Indian biosimilar G-CSF manufacturers have made these essential medicines significantly more affordable.

Pain Management in Oncology

The WHO analgesic ladder — from non-opioid analgesics through weak opioids to strong opioids — provides the framework for cancer pain management. Morphine, Fentanyl, and Oxycodone are key strong opioids. Access to opioid analgesics remains a significant challenge in India despite their essential medicine status.

Immunosuppressants: Precision Medicine for Complex Conditions

Immunosuppressant medicines are used in two major clinical contexts: organ transplantation (to prevent rejection) and autoimmune disease management (to suppress pathological immune activity). Both applications require medicines with narrow therapeutic windows, demanding the highest manufacturing quality standards.

Calcineurin Inhibitors

Tacrolimus and Cyclosporine are the primary immunosuppressive agents used in solid organ transplantation. Tacrolimus has largely replaced Cyclosporine in most transplant centres due to its superior efficacy in preventing acute rejection. Both require regular therapeutic drug monitoring (TDM) to maintain concentrations within the narrow therapeutic range.

Antiproliferative Agents

Mycophenolate Mofetil (MMF) and Azathioprine are used as adjunctive immunosuppression in transplantation and as steroid-sparing agents in autoimmune diseases including lupus nephritis, vasculitis, and myositis.

mTOR Inhibitors

Sirolimus (Rapamycin) and Everolimus are used in renal transplantation, particularly in patients with calcineurin inhibitor-related nephrotoxicity, and as targeted agents in certain malignancies.

Biologics and Biosimilars: Democratising Advanced Therapies

Biologic medicines — produced from living cells using biotechnology — have transformed the treatment of conditions like rheumatoid arthritis, inflammatory bowel disease, psoriasis, and several cancers. However, their high cost has historically limited access, particularly in lower-income countries.

India's pharmaceutical industry has emerged as a global leader in biosimilar development and manufacturing, producing high-quality, affordable biosimilar versions of key biologics including:

• Adalimumab biosimilars: For rheumatoid arthritis, Crohn's disease, psoriasis
• Rituximab biosimilars: For B-cell lymphomas and autoimmune conditions
• Trastuzumab biosimilars: For HER2-positive breast cancer
• Bevacizumab biosimilars: For colorectal cancer and other solid tumours
• Erythropoietin and G-CSF biosimilars: Widely used in oncology and nephrology

Advanced Dermatology: Specialty Formulations for Skin Conditions

Specialty dermatological conditions including moderate-to-severe psoriasis, atopic dermatitis, and complex wound management require sophisticated pharmacological approaches beyond conventional topical therapy:

• Systemic agents for psoriasis: Methotrexate, Acitretin, Cyclosporine, and biologic agents (Adalimumab, Secukinumab, Ixekizumab)
• Dupilumab for atopic dermatitis: The first approved biologic for moderate-to-severe eczema, now available as a biosimilar
• Advanced wound care: Hydrocolloid dressings, silver-containing antimicrobial dressings, and growth factor preparations for chronic wounds

Kasdap Healthcare's Specialty & Advanced Portfolio

Kasdap Healthcare's Specialty & Advanced segment addresses complex therapeutic needs with quality-assured formulations including oncology supportive care, immunosuppressants, and advanced dermatology products — all distributed through a structured healthcare network with appropriate cold chain capabilities where required.